Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascentage Pharma Group International ( (HK:6855) ) has provided an announcement.
Ascentage Pharma Group International has announced a board meeting scheduled for August 20, 2025, to consider and potentially approve the unaudited interim results for the first half of the year. This meeting is significant as it may impact the company’s financial outlook and provide insights into its operational performance, potentially influencing stakeholder decisions.
The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for cancer, hepatitis B, and age-related diseases. The company operates in the pharmaceutical industry and is known for its innovative approach to drug development.
Average Trading Volume: 5,585,846
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.84B
Find detailed analytics on 6855 stock on TipRanks’ Stock Analysis page.